Study Population and Trial Profile
VTE
Of 269 patients in this clinical trial (mean [SD] age, 40.0 [12.1] years; 216 female [80.3%] and 53 male [19.7%]; mean body mass index, 42.2), 134 patients (50.0%) received a 7-day and 135 patients (50%) received a 28-day VTE prophylaxis course with rivaroxaban. Baseline and surgical characteristics are presented in 